The UK has approved Pfizer’s COVID-19 pill for adults who have mild to moderate infection and are at high risk of their illness worsening, its second easily administered antiviral against the coronavirus.
France is seeing ‘tidal wave’ of COVID-19 infections: French Health Min
Never-before-seen surges in COVID-19 infections in France are leading French people to get jabs as soon as possible. Vaccinations are regarded as…
The UK is scrambling to build its defences amid observing a daily record of new COVID-19 cases on Thursday. Government data showed a surge in COVID-19 cases in the winter season as the Omicron variant of the SARS-CoV-2 coronavirus spreads quickly.
Based on data, the pill, Paxlovid, is most effective when taken during the early stages of COVID-19, Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) said on Friday, recommending it be used within five days of the first symptoms.
According to Pfizer, Paxlovid showed near 90 percent efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.
The MHRA said it is working with Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech, to track Paxlovid’s effectiveness against Omicron.
Paxlovid is made of two active substances which come as two separate pills taken twice a day together for five days. The UK has secured more than 2.75 million courses of antiviral treatment.
The Pfizer tablets are part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses, which work by stopping the virus from replicating.
Earlier, the COVID-19 pill by Merck was approved by the UK last month but that drug only reduced hospitalisations and deaths in its clinical trial of high-risk patients by around 30 percent.